LUNG
Pulmonx Corporation NASDAQ Listed Oct 1, 2020$1.27
Mkt Cap $51.7M
52w Low $1.17
3.8% of range
52w High $3.78
50d MA $1.39
200d MA $1.65
P/E (TTM)
—
EV/EBITDA
—
P/B
0.9x
Debt/Equity
1.0x
ROE
-99.8%
P/FCF
-1.6x
RSI (14)
27.10
ATR (14)
$0.11
Beta
0.19
50d MA
$1.39
200d MA
$1.65
Avg Volume
400.5K
Pulmonx Corporation, a medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
700 Chesapeake Drive · Redwood City, CA 94063 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | AMC | -0.33 | -0.33 | +0.0% | 1.20 | -1.7% | +6.7% | +5.5% | -1.5% | -4.5% | +1.6% | — |
| Mar 4, 2026 | AMC | -0.39 | -0.25 | +35.9% | 1.44 | +0.7% | +11.8% | +25.5% | -9.9% | -1.6% | +0.6% | — |
| Nov 12, 2025 | AMC | -0.40 | -0.34 | +15.0% | 1.96 | -1.5% | -18.9% | -6.3% | -8.7% | +2.9% | -1.4% | — |
| Jul 30, 2025 | AMC | -0.40 | -0.38 | +5.0% | 3.15 | -36.8% | -41.6% | -12.5% | +2.5% | -0.6% | -1.8% | — |
| Apr 30, 2025 | AMC | -0.37 | -0.36 | +2.7% | 4.83 | +7.9% | -21.9% | +0.0% | -5.0% | -3.9% | +7.0% | — |
| Feb 19, 2025 | AMC | -0.45 | -0.33 | +26.7% | 6.64 | +14.5% | +32.2% | +2.1% | -0.4% | -2.7% | +6.2% | — |
| Oct 30, 2024 | AMC | -0.43 | -0.36 | +16.3% | 6.79 | -0.6% | -8.0% | +0.3% | +13.6% | -0.1% | +8.4% | — |
| Jul 31, 2024 | AMC | -0.41 | -0.39 | +4.9% | 6.91 | +0.1% | -6.1% | -1.5% | -6.6% | -0.7% | -1.2% | — |
| May 1, 2024 | AMC | -0.43 | -0.36 | +16.3% | 7.72 | +29.3% | +21.5% | +4.7% | -5.5% | +2.7% | -7.6% | — |
| Feb 21, 2024 | AMC | -0.39 | -0.36 | +7.7% | 14.50 | -2.1% | -18.2% | -8.9% | -3.9% | -2.6% | -7.5% | — |
| Oct 30, 2023 | AMC | -0.45 | -0.39 | +13.3% | 7.89 | +10.9% | +11.4% | +3.3% | +3.2% | +5.9% | -3.1% | — |
| Aug 2, 2023 | AMC | -0.43 | -0.43 | +0.0% | 13.23 | +5.7% | +0.2% | +0.1% | -4.1% | -5.0% | -7.0% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | D. Boral Capital | Maintains | Buy → Buy | — | $1.20 | $1.18 | -1.7% | +6.7% | +5.5% | -1.5% | -4.5% | +1.6% |
| Mar 5 | D. Boral Capital | Maintains | Buy → Buy | — | $1.44 | $1.45 | +0.7% | +11.8% | +25.5% | -9.9% | -1.6% | +0.6% |
| Mar 5 | Canaccord Genuity | Maintains | Buy → Buy | — | $1.44 | $1.45 | +0.7% | +11.8% | +25.5% | -9.9% | -1.6% | +0.6% |
| Feb 20 | D. Boral Capital | Maintains | Buy → Buy | — | $1.42 | $1.43 | +0.7% | +6.3% | -2.0% | +2.0% | +7.9% | +0.6% |
| Nov 13 | D. Boral Capital | Maintains | Buy → Buy | — | $1.96 | $1.93 | -1.5% | -18.9% | -6.3% | -8.7% | +2.9% | -1.4% |
| Oct 28 | Lake Street | Maintains | Buy → Buy | — | $1.56 | $1.88 | +20.5% | +26.9% | -3.0% | -8.3% | +13.6% | -8.5% |
| Oct 28 | D. Boral Capital | Maintains | Buy → Buy | — | $1.56 | $1.88 | +20.5% | +26.9% | -3.0% | -8.3% | +13.6% | -8.5% |
| Sep 8 | D. Boral Capital | Maintains | Buy → Buy | — | $1.74 | $1.72 | -1.1% | -2.3% | -0.6% | -4.7% | +5.0% | +0.6% |
| Aug 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $1.84 | $1.85 | +0.5% | -12.5% | +2.5% | -0.6% | -1.8% | +0.6% |
| Jul 31 | Piper Sandler | Downgrade | Overweight → Neutral | — | $3.15 | $1.99 | -36.8% | -41.6% | -12.5% | +2.5% | -0.6% | -1.8% |
| Jul 31 | Lake Street | Maintains | Buy → Buy | — | $3.15 | $1.99 | -36.8% | -41.6% | -12.5% | +2.5% | -0.6% | -1.8% |
| Jul 31 | Stifel | Maintains | Buy → Buy | — | $3.15 | $1.99 | -36.8% | -41.6% | -12.5% | +2.5% | -0.6% | -1.8% |
| Jul 31 | D. Boral Capital | Maintains | Buy → Buy | — | $3.15 | $1.99 | -36.8% | -41.6% | -12.5% | +2.5% | -0.6% | -1.8% |
| May 22 | Citigroup | Maintains | Neutral → Neutral | — | $3.14 | $3.09 | -1.6% | -0.6% | -0.3% | -0.6% | -4.2% | +8.1% |
| May 1 | D. Boral Capital | Maintains | Buy → Buy | — | $4.83 | $5.21 | +7.9% | -21.9% | +0.0% | -5.0% | -3.9% | +7.0% |
| May 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $4.83 | $5.21 | +7.9% | -21.9% | +0.0% | -5.0% | -3.9% | +7.0% |
| May 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $4.83 | $5.21 | +7.9% | -21.9% | +0.0% | -5.0% | -3.9% | +7.0% |
| Mar 11 | D. Boral Capital | Maintains | Buy → Buy | — | $7.22 | $7.22 | +0.0% | +1.1% | +0.3% | -3.7% | +6.7% | +3.6% |
| Feb 20 | Citigroup | Maintains | Neutral → Neutral | — | $6.64 | $7.60 | +14.5% | +32.2% | +2.1% | -0.4% | -2.7% | +6.2% |
| Dec 11 | Citigroup | Downgrade | Buy → Neutral | — | $6.58 | $6.17 | -6.2% | -2.9% | -5.3% | +0.8% | +1.6% | -1.1% |
| Dec 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $6.58 | $6.17 | -6.2% | -2.9% | -5.3% | +0.8% | +1.6% | -1.1% |
| Oct 31 | Stifel | Maintains | Buy → Buy | — | $6.79 | $6.75 | -0.6% | -8.0% | +0.3% | +13.6% | -0.1% | +8.4% |
| Aug 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $6.91 | $6.92 | +0.1% | -6.1% | -1.5% | -6.6% | -0.7% | -1.2% |
| Aug 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $6.91 | $6.92 | +0.1% | -6.1% | -1.5% | -6.6% | -0.7% | -1.2% |
| Aug 1 | Canaccord Genuity | Maintains | Buy → Buy | — | $6.91 | $6.92 | +0.1% | -6.1% | -1.5% | -6.6% | -0.7% | -1.2% |
| May 2 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.72 | $9.98 | +29.3% | +21.5% | +4.7% | -5.5% | +2.7% | -7.6% |
| Apr 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $8.51 | $8.56 | +0.6% | -6.6% | -1.1% | +4.8% | +1.8% | +3.1% |
| Feb 23 | Citigroup | Maintains | Buy → Buy | — | $11.86 | $11.36 | -4.2% | -8.9% | -3.9% | -2.6% | -7.5% | -1.5% |
| Feb 23 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $11.86 | $11.36 | -4.2% | -8.9% | -3.9% | -2.6% | -7.5% | -1.5% |
| Feb 22 | Wells Fargo | Maintains | Overweight → Overweight | — | $14.50 | $14.20 | -2.1% | -18.2% | -8.9% | -3.9% | -2.6% | -7.5% |
| Feb 22 | Stifel | Maintains | Buy → Buy | — | $14.50 | $14.20 | -2.1% | -18.2% | -8.9% | -3.9% | -2.6% | -7.5% |
| Feb 22 | Piper Sandler | Maintains | Overweight → Overweight | — | $14.50 | $14.20 | -2.1% | -18.2% | -8.9% | -3.9% | -2.6% | -7.5% |
| Oct 31 | Canaccord Genuity | Maintains | Buy → Buy | — | $7.89 | $8.75 | +10.9% | +11.4% | +3.3% | +3.2% | +5.9% | -3.1% |
| Oct 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $7.89 | $8.75 | +10.9% | +11.4% | +3.3% | +3.2% | +5.9% | -3.1% |
| Aug 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $13.23 | $13.99 | +5.7% | +0.2% | +0.1% | -4.1% | -5.0% | -7.0% |
| Jul 11 | Citigroup | Maintains | Buy → Buy | — | $12.99 | $13.09 | +0.8% | +2.4% | +2.6% | -3.2% | +2.0% | -1.1% |
| May 3 | Citigroup | Maintains | Buy → Buy | — | $11.47 | $12.85 | +12.0% | +8.6% | -1.9% | +0.6% | +1.1% | +1.2% |
| May 3 | Piper Sandler | Maintains | Overweight → Overweight | — | $11.47 | $12.85 | +12.0% | +8.6% | -1.9% | +0.6% | +1.1% | +1.2% |
| May 3 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.47 | $12.85 | +12.0% | +8.6% | -1.9% | +0.6% | +1.1% | +1.2% |
| Apr 3 | Citigroup | Maintains | Buy → Buy | — | $11.18 | $11.40 | +2.0% | -2.8% | -0.8% | +1.7% | +2.2% | -1.9% |
| Feb 27 | Wells Fargo | Upgrade | Equal Weight → Overweight | — | $10.37 | $11.15 | +7.5% | +6.0% | +2.2% | +2.2% | -0.8% | +4.1% |
| Feb 24 | Citigroup | Maintains | Buy → Buy | — | $10.53 | $10.41 | -1.1% | -1.5% | +6.0% | +2.2% | +2.2% | -0.8% |
| Feb 23 | Canaccord Genuity | Maintains | Buy → Buy | — | $8.76 | $12.24 | +39.7% | +20.2% | -1.5% | +6.0% | +2.2% | +2.2% |
| Feb 23 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $8.76 | $12.24 | +39.7% | +20.2% | -1.5% | +6.0% | +2.2% | +2.2% |
| Jan 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $7.93 | $7.96 | +0.4% | -1.8% | +3.6% | +5.8% | +1.1% | +0.6% |
| Jan 3 | BofA Securities | Downgrade | Neutral → Underperform | — | $8.43 | $7.84 | -7.0% | -11.2% | +10.1% | -3.9% | -1.8% | +3.6% |
| Dec 12 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $5.88 | $6.25 | +6.3% | +8.0% | +9.4% | -1.6% | +4.4% | +3.5% |
| Dec 12 | Citigroup | Upgrade | Neutral → Buy | — | $5.88 | $6.25 | +6.3% | +8.0% | +9.4% | -1.6% | +4.4% | +3.5% |
| Nov 7 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $4.82 | $4.71 | -2.3% | +3.5% | +6.4% | -7.2% | +15.8% | +14.4% |
| Nov 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $12.34 | $10.00 | -19.0% | -60.9% | +3.5% | +6.4% | -7.2% | +15.8% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2026 | French Glendon E. III | President and CEO | Sell | 13,511 | $1.57 | $21K | 1,178,162 | +6.58% | -6.54% |
| Jun 1, 2026 | Lehman David Aaron | GENERAL COUNSEL | Sell | 4,915 | $1.54 | $8K | 376,161 | +6.58% | -6.54% |
| Jun 1, 2026 | Lehman David Aaron | GENERAL COUNSEL | Sell | 3,539 | $1.54 | $5K | 381,076 | +6.58% | -6.54% |
| Jun 1, 2026 | Lehman David Aaron | GENERAL COUNSEL | Sell | 2,264 | $1.54 | $3K | 384,615 | +6.58% | -6.54% |
| Jun 1, 2026 | Lehman David Aaron | GENERAL COUNSEL | Sell | 3,876 | $1.54 | $6K | 386,879 | +6.58% | -6.54% |
| Jun 1, 2026 | Rose Geoffrey Beran | CHIEF COMMERCIAL OFFICER | Sell | 2,254 | $1.54 | $3K | 457,711 | +6.58% | -6.54% |
| Jun 1, 2026 | Rose Geoffrey Beran | CHIEF COMMERCIAL OFFICER | Sell | 2,434 | $1.54 | $4K | 459,965 | +6.58% | -6.54% |
| Jun 1, 2026 | Rose Geoffrey Beran | CHIEF COMMERCIAL OFFICER | Sell | 1,557 | $1.54 | $2K | 462,399 | +6.58% | -6.54% |
| Jun 1, 2026 | Rose Geoffrey Beran | CHIEF COMMERCIAL OFFICER | Sell | 1,778 | $1.54 | $3K | 463,956 | +6.58% | -6.54% |
| Jun 1, 2026 | French Glendon E. III | President and CEO | Sell | 38,467 | $1.54 | $59K | 1,191,673 | +6.58% | -6.54% |
| Jun 1, 2026 | French Glendon E. III | President and CEO | Sell | 4,171 | $1.54 | $6K | 1,230,140 | +6.58% | -6.54% |
| Jun 1, 2026 | Radhakrishnan Srikanth | Chief Science &Techn. Officer | Sell | 5,969 | $1.54 | $9K | 331,239 | +6.58% | -6.54% |
| Jun 1, 2026 | Radhakrishnan Srikanth | Chief Science &Techn. Officer | Sell | 3,684 | $1.54 | $6K | 337,208 | +6.58% | -6.54% |
| Jun 1, 2026 | Radhakrishnan Srikanth | Chief Science &Techn. Officer | Sell | 2,153 | $1.54 | $3K | 340,892 | +6.58% | -6.54% |
| Jun 1, 2026 | Radhakrishnan Srikanth | Chief Science &Techn. Officer | Sell | 2,691 | $1.54 | $4K | 343,045 | +6.58% | -6.54% |
8-K
Pulmonx Corporation -- 8-K Filing
Pulmonx Corporation reported Q1 2026 revenue of $20.6 million, down 9% year-over-year, indicating slowing growth momentum for the minimally invasive lung disease treatment company.
Apr 29
8-K · 1.01
! Medium
Pulmonx Corporation -- 8-K 1.01: Financing / Debt Agreement
Pulmonx Corporation secured a $60 million credit facility, providing additional liquidity to support operations and potentially fund strategic initiatives or debt refinancing.
Mar 5
8-K
Pulmonx Corporation -- 8-K Filing
Pulmonx strengthened its balance sheet in 2025 while refocusing investments on growth opportunities, demonstrating improved financial discipline as the minimally invasive lung disease treatment leader.
Mar 4
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 8,320,938 | $18M | Added | Dec 2025 |
| 2 | Primecap Management Co/ca/ | 4,724,991 | $6M | — | Mar 2026 |
| 3 | Soleus Capital Management, L.p. | 2,788,323 | $4M | Added | Mar 2026 |
| 4 | Vanguard Capital Management Llc | 1,634,264 | $2M | New | Mar 2026 |
| 5 | Braidwell Lp | 752,541 | $2M | — | Dec 2025 |
| 6 | Bank Of America Corp /de/ | 1,166,826 | $2M | Added | Mar 2026 |
| 7 | Stonepine Capital Management, Llc | 768,288 | $991K | Added | Mar 2026 |
| 8 | Barclays Plc | 683,435 | $882K | Added | Mar 2026 |
| 9 | Vanguard Portfolio Management Llc | 604,455 | $780K | New | Mar 2026 |
| 10 | Cfm Wealth Partners Llc | 264,039 | $584K | — | Dec 2025 |
| 11 | Adar1 Capital Management, Llc | 374,497 | $483K | New | Mar 2026 |
| 12 | Aqr Capital Management Llc | 357,578 | $461K | Added | Mar 2026 |
| 13 | Jpmorgan Chase & Co | 388,103 | $458K | Reduced | Mar 2026 |
| 14 | Northern Trust Corp | 354,674 | $458K | Added | Mar 2026 |
| 15 | D.e. Shaw & Co | 335,074 | $432K | Reduced | Mar 2026 |
| 16 | Renaissance Technologies Llc | 320,300 | $413K | Added | Mar 2026 |
| 17 | Jane Street Group, Llc | 164,971 | $365K | Reduced | Dec 2025 |
| 18 | Ubs Group Ag | 209,701 | $271K | Added | Mar 2026 |
| 19 | Acadian Asset Management Llc | 166,341 | $212K | Reduced | Mar 2026 |
| 20 | Centiva Capital, Lp | 153,882 | $199K | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$51.7M
Enterprise Value
$18.7M
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.22x
P/B
0.95x
P/S
0.58x
P/FCF
-1.57x
EV/EBITDA
—
Shares Out
40.7M
Financials (TTM)
Revenue
$88.5M
Net Income
-$53.2M
EBITDA
-$48.2M
Free Cash Flow
-$32.9M
Op Cash Flow
-$32.4M
EPS Basic
$-1.33
EPS Diluted
$-1.30
EPS Forward
$-1.10
Gross Margin
75.5%
Op Margin
-58.8%
Net Margin
-60.1%
Balance Sheet
Total Assets
$129.3M
Total Liab.
$75.2M
Total Equity
$54.1M
Cash
$70.0M
LT Debt
$37.0M
Book Value/Sh
$1.33
Debt/Equity
1.04x
Current Ratio
5.07
Quick Ratio
4.28
Returns & Growth
ROE
-99.8%
ROA
-41.8%
ROIC
-48.5%
Rev Growth YoY
+8.0%
EPS Growth YoY
+7.6%
Price Returns
2W
+23.1%
1M
+28.9%
3M
+4.4%
6M
+1.9%
12M
-51.5%
Technicals
52W High
$3.78
52W Low
$1.17
50d MA
$1.39
200d MA
$1.65
RSI (14)
27.10
ATR (14)
$0.11
Beta
0.19
Avg Volume
401K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$10.00
High
$20.00
Low
$2.50
Median
$9.75
Data updated apr 25, 2026 8:05pm
· Source: financialmodelingprep.com